241 related articles for article (PubMed ID: 36305439)
1. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
2. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
Montalvo I; Llorens M; Caparrós L; Pamias M; Torralbas J; Giménez-Palop O; Caixàs A; Palao DJ; Labad J
Int Clin Psychopharmacol; 2018 Mar; 33(2):98-102. PubMed ID: 29035904
[TBL] [Abstract][Full Text] [Related]
3. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
6. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
7. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
9. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
10. Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
van Uum SH; van Alfen N; Wesseling P; van Lindert E; Pieters GF; Nooijen P; Hermus AR
J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1489-91. PubMed ID: 15377706
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
12. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
13. True hyperprolactinemia in men without visible pituitary adenoma.
Shimon I; Rudman Y; Manisterski Y; Gorshtein A; Masri H; Duskin-Bitan H
Endocrine; 2021 Jun; 72(3):809-813. PubMed ID: 33566310
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
[TBL] [Abstract][Full Text] [Related]
15. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
17. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
18. Management of prolactinomas in children and adolescents; which factors define the response to treatment?
Alikasifoglu A; Celik NB; Ozon ZA; Gonc EN; Kandemir N
Pituitary; 2022 Feb; 25(1):167-179. PubMed ID: 34518999
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
